4//SEC Filing
Burgess Michael F. 4
Accession 0001104659-22-002741
CIK 0001773427other
Filed
Jan 9, 7:00 PM ET
Accepted
Jan 10, 4:23 PM ET
Size
7.4 KB
Accession
0001104659-22-002741
Insider Transaction Report
Form 4
Burgess Michael F.
Head of Research & Development
Transactions
- Award
Common Stock
2022-01-06+15,674→ 43,174 total - Award
Stock Option (Right to Buy)
2022-01-06+48,852→ 48,852 totalExercise: $59.46Exp: 2032-01-06→ Common Stock (48,852 underlying)
Footnotes (2)
- [F1]This transaction represents a grant of restricted stock units ("RSUs"). The RSUs shall vest as follows: thirty three percent (33%) to vest on January 6, 2023, another thirty three percent (33%) to vest on January 6, 2024 and the remaining thirty four percent (34%) to vest on January 6, 2025, such that the restricted stock awards are fully vested on January 6, 2025.
- [F2]This option shall vest in 48 equal monthly installments subject to continued service to the company by the Reporting Person.
Documents
Issuer
SpringWorks Therapeutics, Inc.
CIK 0001773427
Entity typeother
Related Parties
1- filerCIK 0001801745
Filing Metadata
- Form type
- 4
- Filed
- Jan 9, 7:00 PM ET
- Accepted
- Jan 10, 4:23 PM ET
- Size
- 7.4 KB